DP-Next newsletter June 2026
New members of the team
- Michella Ravn Søndergaard - PhD student WP3 SDCC/SDCG
- Elpida Vounzoulaki, Post Doc. WP2 SDCA
- Mikkel Errboe Steentoft, Master student, WP3 SDCA
- Christian Tjørnehøj, Trainee, SDCA
Meeting September 24
As announced previously we will be hosting a one day hybrid meeting at SDCA on September 24, with open to all participants and with participation of our advisory board (Robert Wagner, Sarah Wild, and Steven Allender). The meeting will be followed by dinner in the evening. If you have not already done so, read more and sign up for the meeting at: DP-Next meeting 24 September signup
Collaboration agreement + Joint data controller agreement
The collaboration agreement and joint data controller agreement for all Danish centers are signed and we are working on getting the agreements with Faroe Islands and Greenland in place.
Publication strategy
A draft of the publication strategy have been developed and is accessible at:
Please let us know if you have any comment on this before we finalize this.
Questionnaire
The WP3 questionnaire will be sent out to all 40-49 years old with prediabetes ~ 12.000 and a random subset of 50.000 persons with recent HbA1c measurements. The first test batch of 1.500 questionnaires has been sent out. We expect in total ~ 30.000 responses and will have these baseline data available for initial analyses in the fall 2026.
Clinical examination
The WP3 clinical examination planning is ongoing, and VEK application has been submitted. We plan to start recruiting participants in DK in the fall.
Flowchart
Christian Tjørnehøj has worked on visualizing the selection steps and estimated participant numbers for the WP3 Questionnaire and Clinical Examination cohorts:
DP-next at EDEG
DP-Next researchers presented the first DP-next related results at EDEG 2026:
Kristina Matthiesen Hansen: Prevalence of prediabetes and diabetes based on routine HbA1c measurements in the Faroese population aged 30-80 years.
Jonas R. Schaarup: Distinct roles of endogenous incretin and glucagon responses to oral glucose tolerance test in association with cardiovascular risk: 11-year follow-up of the ADDITION-PRO study.